Dr. Khalid Matin, MD

Dr. Matin practices at VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia.

Dr. Matin's NPI, 1952375891, was assigned on February 16, 2006. Dr. Matin holds Virginia license 0101254340.

Dr. Matin's primary practice is VCU Medical Center, at 1250 East Marshall Street, Richmond, VA 23298 in Richmond City. The practice phone is (804) 828-9000.

Dr. Matin's primary practice is VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia. Dr. Matin is also affiliated with VCU Health Tappahannock Hospital. The medical group on file is MCV Physicians. Dmand AI also links Dr. Matin to 1 more urgent care center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Matin practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Matin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Matin is licensed in Virginia.

CMS data shows 308 Medicare services from Dr. Matin across 3 procedure codes in 2024, for 160 Medicare patients. Medicare paid $23,816 for them.

CMS counts 160 Medicare patients who saw Dr. Matin in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Matin's median patient age at 73, with 43% women.

In 2024, Dr. Matin wrote 398 Medicare Part D claims for 86 patients. 83% of them were for generic drugs. CMS names the drug for 250 of them, across 10 drugs with 11 or more claims each, at $245,745 in total drug cost. In 2023, CMS named 176 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Matin for performance year 2024, reported as part of a group. Dr. Matin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Matin as offering telehealth.

Dmand AI links 14 papers to Dr. Matin, published from 2011 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Anticoagulants, Interviews as Topic and Medical Oncology. Dr. Matin has published most often in Catheter Cardiovasc Interv. Dr. Matin's most frequent co-authors are Lori Jo Pierce, MD, Hanna K. Sanoff, MD and Raza Askari.

Dmand AI links Dr. Matin to 6 clinical trials, 5 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Anus Neoplasms and Colorectal Neoplasms. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 21 general payments to Dr. Matin from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. Taiho Oncology, Inc. paid the most, $9,775. It also lists 1 research payment totaling $111 in 2023.